Global Staphylococcal Infection Drugs Market 2019-2023
About this market
Regulatory agencies are granting special drugs designations for the development of drugs for the treatment of infectious diseases, including those used for the treatment of staphylococcal infection. Special drug designations offer incentives for the development of new drugs for the treatment which is encouraging more and more manufacturers to invest in the development of drugs, which in turn is driving the market. Technavio’ s analysts have predicted that the staphylococcal infection drugs market will register a CAGR of nearly 3% by 2023.
Increasing incidence of staphylococcal infections
The emergence of antibiotics resistant strains has led to increased incidence of staphylococcal infections. Skin and soft tissue infections are the most common type of infections caused by staphylococcal. Thus, rising incidence of staphylococcal infections is a major driver contributing to the market growth.
Lack of vaccines and new drug classes
Unlike most of the infectious diseases that can be prevented by vaccines, there is no approved vaccine for the prevention of staphylococcal infections. The rapid evolution of the bacteria responsible along with the following factors pose a major hurdle to the development of vaccines against staphylococcal infections.
For the detailed list of factors that will drive and challenge the growth of the staphylococcal infection drugs market during the 2019-2023, view our report.
The market appears to be fragmented and with the presence of several companies including Merck & Co. Inc. and Pfizer Inc the competitive environment is quite intense. Factors such as the increasing incidence of staphylococcal infections and special drug designations, will provide considerable growth opportunities to staphylococcal infection drugs manufactures. Allergan Plc, Bayer AG, GlaxoSmithKline Plc, Merck & Co. Inc., and Pfizer Inc. are some of the major companies covered in this report.
Technavio Announces the Publication of its Research Report – Global Staphylococcal Infection Drugs Market 2019-2023
Technavio recognizes the following companies as the key players in the global staphylococcal infection drugs market: Allergan Plc, Bayer AG, GlaxoSmithKline Plc, Merck & Co. Inc., and Pfizer Inc.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is the expanding R&D of novel therapies.”
According to the report, one of the major drivers for this market is the increasing incidence of staphylococcal infections.
Further, the report states that one of the major factors hindering the growth of this market is the lack of vaccines and new drug classes.
Merck & Co. Inc.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook